Meantime, the flurry of mergers and acquisition activity that began late last year and which launched the biotech sector into overdrive has slowed noticeably. Investors are still waiting to see whether hepatitis C developers Idenix Pharmaceuticals (IDIX) and Achillion Pharmaceuticals (ACHN) are taken out following similar deals for Pharmasset and Inhibitex.
9 Oil, Gold Stocks That Rise on Bad News
Where has all the good new in biotech gone?
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein.
>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.